June 20, 2016
(Nature) – Ten years on, the goals have shifted — in part because those therapies have proved challenging to develop. The only clinical trial using iPS cells was halted in 2015 after just one person had received a treatment. But iPS cells have made their mark in a different way. They have become an important tool for modelling and investigating human diseases, as well as for screening drugs. Improved ways of making the cells, along with gene-editing technologies, have turned iPS cells into a lab workhorse — providing an unlimited supply of once-inaccessible human tissues for research. This has been especially valuable in the fields of human development and neurological diseases, says Guo-li Ming, a neuroscientist at Johns Hopkins University in Baltimore, Maryland, who has been using iPS cells since 2006.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.